Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately…
Bristol Myers Squibb (NYSE: BMY) has received approval from the U.S. Food and Drug Administration (FDA) for COBENFY™ (xanomeline and trospium chloride), marking a significant advancement in the treatment of…
The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype and…
AstraZeneca’s Tagrisso (osimertinib) has received U.S. approval for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), whose disease has…
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III REGENCY study of Gazyva®/Gazyvaro® (obinutuzumab) in patients with active lupus nephritis. The study revealed that…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the Phase 3 KEYFORM-007 trial, which investigated the fixed-dose combination of favezelimab (Merck’s anti-LAG-3 antibody) and…
BioAlberta is excited to announce a new partnership with AxialBridge as its operational and commercialization partner. This collaboration aims to assist Alberta-based biotechnology and MedTech companies in expanding their clinical…
eClinical Solutions LLC, a global leader in digital clinical software and services, is set to host its sixth annual client and partner conference, ENGAGE 2024, on Thursday, October 10 and…
Phare Bio, in collaboration with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard’s Wyss Institute, has secured up to $27 million in funding from the Advanced…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized the positive…
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for treating schizophrenia in adults.…
In recognition of World Dense Breast Day on September 25, Bayer has announced a new study, published in Patient Preference and Adherence, that explores gaps in awareness and knowledge of…